S&P 500 Healthcare Sector SEC Filings — March 26, 2026

26-03-2026

Alto Neuroscience, Inc. (ANRO) issued a DEFA14A notice for its upcoming stockholder meeting, proposing to elect Raymond Sanchez, M.D. and Gwill York as Class II Directors to serve until the 2029 Annual Meeting, ratify Deloitte & Touche LLP as the independent auditor for the year ending December 31, 2026, and approve amendments to the 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan to treat pre-funded warrants as outstanding common stock for evergreen share reserve calculations. The Board recommends voting FOR all four proposals. No financial metrics or performance data are disclosed in this notice.

• ·Proxy materials request deadline: April 28, 2026
• ·Vote online at www.ProxyVote.com using 12-digit control number
• ·Proxies authorized to vote on other business at meeting or adjournments

26-03-2026

Arcadia Biosciences reported Q4 and FY 2025 financial results showing total revenues declining 26% YoY to $901 thousand in Q4 and 4% YoY to $4,858 thousand for the full year, despite Zola revenues increasing 17% YoY by $701 thousand driven by higher distribution volume. Operating expenses fell 35% in Q4 and 15% for FY, with SG&A down 27% and net cash used in operations down 49%, improving loss from continuing operations by 40% in Q4 and 31% FY, and net loss to $1.3 million ($0.97/share) in Q4 and $2.3 million ($1.71/share) FY. The company terminated its proposed business combination with Roosevelt Resources and received $2.1 million gross proceeds from the exercise of preferred investment options to support Zola growth and strategic alternatives.

• ·Cost of revenues decreased 14% in Q4 2025 YoY but increased 5% for FY 2025 YoY.
• ·Q4 2025 net loss $0.97 per share vs $2.98 prior year; FY 2025 $1.71 per share vs $5.17.
• ·Other operating expenses increased $1.2M FY 2025 due to absence of $4.0M Corteva gain in 2024, offset by $750K Bioceres gain and $2.0M contingent liability reduction in 2025.
• ·Q4 2024 revenues included $55K GLA oil sales absent in 2025; FY 2024 included $756K GLA oil sales absent in 2025.

26-03-2026

Newsmax reported record FY 2025 revenues of $189.3 million, up 10.7% YoY, with broadcast revenues surging 17.3% to $153.3 million driven by advertising (+16.7%) and affiliate fees (+14.9%); however, digital revenues declined 10.9% to $35.9 million amid drops in advertising (-19.0%) and subscriptions (-13.0%). Q4 revenues increased 9.6% to $52.2 million with broadcast up 12.6%, but the company posted a Q4 net loss of $(3.0) million (improved from $(6.9) million) and FY net loss of $(99.5) million due to $79 million legal settlements and investments, alongside negative adjusted EBITDA of $(6.5) million for the year. Newsmax projects FY 2026 revenues of $212-216 million, implying 13% growth at the midpoint.

• ·Ended FY 2025 with total assets of $239.8 million and total liabilities of $133.8 million.
• ·Q4 adjusted EBITDA $(1.3) million, down from prior year.
• ·FY adjusted EBITDA $(6.5) million.
• ·Newsmax ranked fourth highest-rated cable news channel and #6 in total day ratings among all cable channels.

26-03-2026

Newmont Corporation's 2026 Proxy Statement reflects on a strong 2025 with record earnings, free cash flow, all-time high stock price, $1.1B returned to stockholders via dividends, completion of a $3.0B share repurchase program ($2.3B repurchased in 2025), and announcement of an additional $3.0B repurchase program. The company launched the Always Safe program achieving zero fatalities and completed an orderly CEO transition from Tom Palmer to Natascha Viljoen on January 1, 2026. Stockholders will vote on electing 12 directors, advisory approval of executive compensation, and ratification of Ernst & Young LLP as auditors at the virtual annual meeting on May 12, 2026.

• ·Annual Meeting: May 12, 2026, 8:00 a.m. Mountain Daylight Time, virtual at https://meetnow.global/MQD4CLQ
• ·Record Date: March 16, 2026
• ·Proxy materials first sent: On or about March 31, 2026

26-03-2026

Edwards Lifesciences Corporation (EW) has filed a DEFA14A notice making proxy materials available online for its Annual Meeting of Stockholders on May 7, 2026, at 10:00 AM Pacific Time via webcast, for stockholders of record as of March 10, 2026. The agenda includes Proposal 1: Election of nine directors; Proposal 2: Advisory vote to approve named executive officer compensation; Proposal 3: Ratification of the appointment of the independent registered public accounting firm; and Proposal 4: Approval of the Amended and Restated Long-Term Stock Incentive Compensation Program. The Board of Directors recommends a vote FOR all proposals.

• ·Record date: March 10, 2026
• ·Paper material request deadline: April 27, 2026
• ·Proxy materials accessible at www.proxydocs.com/EW; registration required to attend online
• ·Voting requires 12-digit control number

26-03-2026

CV Sciences reported fiscal 2025 revenue of $13.8 million, down 12.2% YoY from $15.7 million due to lower sales volume from out-of-stock issues and regulations, while Q4 revenue was flat QoQ at $3.3 million. Gross margins improved significantly to 49.0% from 45.6% YoY, operating expenses fell 17.2% to $7.7 million (excluding tax reversal benefit), and adjusted EBITDA loss narrowed to -$0.3 million from -$0.8 million, achieving positive $0.1 million in Q4. Cash balance declined to $0.3 million from $0.5 million amid ongoing efforts toward profitability.

• ·Launched 39 new products since January 1, 2023, contributing 39% of FY2025 net revenue.
• ·Net loss of $0.958 million in FY2025 vs. $2.394 million in FY2024.
• ·Inventory at $4.087 million as of Dec 31, 2025, down from $4.897 million.
• ·Completed debt restructuring in Q1 2026.

26-03-2026

Dare Bioscience reported total revenue of $1,030,193 in 2025, up 10,429% YoY from $9,784, driven by license fees, while R&D expenses fell 61% to $5,523,352 and total operating expenses declined 39% to $14,286,728, narrowing operating loss by 43% to $(13,552,334). However, net loss widened 231% to $(13,399,274) from $(4,053,599) due to the absence of 2024's $20,379,376 gain from sale of royalty rights, with operating cash flow turning to a use of $(9,885,870) from provision of $5,473,555. Cash and equivalents rose to $24,711,356, bolstered by $19,277,144 in financing from stock issuance, and stockholders' equity flipped to a positive $2,842,634 from a $(6,012,089) deficit.

• ·Selling, general and administrative expenses declined 4% to $8,763,376.
• ·Total direct program costs fell 69% to $2,958,892.
• ·Contra R&D expenses increased 81% to $(13,919,881).
• ·Deferred grant funding rose to $19,651,452 from $16,561,625.
• ·Loss per common share - basic and diluted: $(1.20) vs $(0.48).
• ·Weighted average common shares outstanding: 11,178,752 vs 8,497,459.

26-03-2026

Stifel Financial Corp. issued a press release on March 26, 2026, disclosing selected operating results for February 28, 2026, under Item 7.01 Regulation FD Disclosure. The press release is furnished as Exhibit 99.1 and not deemed filed. The filing was signed by CFO James M. Marischen.

26-03-2026

Tradeweb Markets Inc. filed a DEFA14A Definitive Additional Proxy Materials on March 26, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing is marked as soliciting material under §240.14a-12 with no fee required. No specific proposals, financial data, or other substantive details are provided in the available content.

26-03-2026

Centene's 2026 proxy statement highlights a challenging 2025 with adjusted diluted EPS of $2.08, below initial outlook due to Medicaid volatility and Marketplace risk pool shifts, prompting program exits and lowered guidance. However, Q4 execution improved results slightly ahead of October expectations, with strong operational metrics including 93.3% member satisfaction from 2.9 million surveys and $38 million in prevented fraudulent payments. Looking to 2026, the company anticipates adjusted diluted EPS exceeding $3.00, representing over 40% YoY growth, alongside $174.6 billion in 2025 premium and service revenues, 27.6 million members, and 61,100 employees.

• ·Annual Meeting: May 12, 2026, 10:00 AM CT at Centene Plaza, St. Louis, MO; Record Date: March 13, 2026.
• ·#1 carrier in Health Insurance Marketplace; #42 FORTUNE GLOBAL 500 (2025); #23 FORTUNE 500 (2025).
• ·Proposals: (1) Elect 9 directors (FOR); (2) Advisory vote on NEO compensation (FOR); (3) Ratify KPMG (FOR); (4) Stockholder proposal (AGAINST).
• ·Double-digit improvements since 2023 in blood pressure, diabetes control, maternal/child health across Medicaid, Medicare, Marketplace.

26-03-2026

Newell Brands Inc. has filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting on May 7, 2026, soliciting votes on the election of eight director nominees, ratification of PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2026, an advisory resolution on named executive officer compensation, and approval of the Newell Brands Inc. 2026 Incentive Plan. The Board recommends voting 'For' all proposals. No financial metrics or performance data are included in this notice.

• ·Meeting location: The Westin Atlanta Perimeter North, 7 Concourse Parkway, NE, Atlanta, Georgia 30328
• ·Vote deadline: May 6, 2026 11:59 PM ET (May 4, 2026 11:59 PM ET for shares held in a Plan)
• ·Proxy materials request deadline: April 23, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com

26-03-2026

On March 20, 2026, H.C. Charles Diao notified Bally’s Chicago, Inc. of his resignation as Chief Financial Officer effective April 1, 2026, to pursue another professional opportunity, with no disagreements on operations, policies, or practices, and no separation agreement. On March 26, 2026, Cheryl R. Ash, age 46, was appointed as the new CFO subject to regulatory approvals; she has over 18 years of experience in the casino-hospitality industry and currently serves as Senior Vice President, Finance, Casinos and Resorts at parent Bally’s Corporation. Ms. Ash’s existing employment agreement provides an annual base salary of $328,214 and a target bonus of 75% of base salary, with no immediate changes anticipated.

• ·H.C. Charles Diao also resigning as Senior Vice President and Treasurer of Bally’s Corporation.
• ·No family relationships between Cheryl R. Ash and any director or executive officer of the Company.
• ·Cheryl R. Ash has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
• ·Cheryl R. Ash holds a Master of Business Administration from Louisiana State University Shreveport and a Bachelor of Science in Accounting from the University of Nevada, Las Vegas.
• ·Appointment of Cheryl R. Ash subject to customary regulatory approvals; future equity grants and potential new employment agreement to be determined.

26-03-2026

YPF's total revenues declined 4.4% YoY to $18,448 million in 2025 from $19,293 million in 2024, driven by drops in Upstream (down to $7,575 million from $8,275 million) and Midstream & Downstream ($15,338 million from $16,023 million), while New Energies revenues fell to $843 million from $904 million. However, operating profit improved 17.6% YoY to $1,740 million from $1,480 million, with strong gains in New Energies (to $432 million from $106 million) and Upstream profitability despite lower revenues; average production costs also decreased to $15.8/boe from $19.5/boe. Downstream sales volumes were nearly flat at 14,119 km3, down 0.1% YoY, with diesel volumes declining 5.7% but premium Infinia diesel up 8.3%.

• ·Logistics pipeline capacities: Puesto Hernández to Luján de Cuyo refinery (528 km, 93,509 boe/d, 100% YPF interest); Puerto Rosales to La Plata refinery (585 km, 326,541 boe/d); La Plata to Dock Sud (52 km, 141,006 boe/d).
• ·Average realized prices 2025: Oil $60.1/boe (down from $68.2), NGLs $27.7/boe (down from $28.8), Natural gas $21.0/boe (down from $21.6).

26-03-2026

Invesco Commercial Real Estate Finance Trust, Inc. reported significant growth in Net Asset Value to $1,088,966 thousand from $614,768 thousand in 2024, with commercial real estate loan investments nearly doubling to $4,702,728 thousand and net income rising to $62,349 thousand. Total distributions increased to $65,076 thousand, fully covered by cash flows from operations of $77,566 thousand. However, earnings per share declined to $1.82 from $1.95, unrealized losses on secured financing facilities reached $23,920 thousand, and cash equivalents dropped to $16,557 thousand from $80,221 thousand.

• ·Number of outstanding shares increased to 43,168,734 from 24,252,394.
• ·Real estate-related securities fair value $14,818 thousand with weighted average yield 6.29%.
• ·Total loans listed: 35 individual investments across multifamily, industrial, and self-storage properties.
• ·Weighted average interest rate on loans ranges from 5.12% to 12.00%.
• ·Net cash provided by operating activities $77,566 thousand in 2025 vs. $47,067 thousand in 2024.

26-03-2026

Oaktree Acquisition Corp. III Life Sciences filed its 10-K annual report on March 26, 2026, detailing SPAC structure including permitted trust withdrawals limited to $250,000 annually (plus rollovers) from interest for working capital and taxes. Sponsor received 4,799,758 founder shares for $25,000 and 583,981 private placement units, with up to $1,500,000 in convertible working capital loans at $10 per unit and uncapped expense reimbursements. Founder shares face transfer restrictions until 180 days post-initial business combination, convertible to 20% ownership on as-converted basis.

• ·Transfer restrictions on founder shares apply to sponsor, directors, and officers until 180 days after initial business combination or liquidation/merger event.
• ·Permitted withdrawals from trust limited to interest earned, not principal.
• ·Private placement shares and warrants are non-redeemable and lack redemption/liquidation rights if no business combination.
• ·Uncapped reimbursement for sponsor/officers/directors out-of-pocket expenses related to business combination activities.
• ·Working capital loans conversion at $10/unit and $11.50 warrant exercise price may cause dilution to public shareholders.

26-03-2026

New Mountain Private Credit Fund sold 124,843 common shares for total consideration of $2,980,000 at $23.87 per share in its continuous private offering as of March 2026. The Board declared a regular distribution of $0.19 per share, payable on or about April 30, 2026 to shareholders of record as of March 31, 2026. As of February 28, 2026, NAV per share was $23.87, with aggregate NAV of approximately $1,014.1 million, investment portfolio fair value of $2,062.4 million, and debt outstanding of $1,094.8 million at an average leverage ratio of 1.07 times.

• ·Average debt-to-equity leverage ratio during February 2026 was approximately 1.07 times.
• ·Committed debt capacity of $1,435.0 million consists of 100% floating rate leverage, with 79% secured and 21% unsecured based on drawn amounts.
• ·Certain notes classified as floating rate due to interest rate swaps.

26-03-2026

Principal Credit Real Estate Income Trust reported Total NAV of $110,162 thousand as of December 31, 2025, supported by investments in loans receivable at $377,308 thousand, up significantly since inception. For the year ended December 31, 2025, total revenue increased 1,242% to $24,491 thousand from $1,825 thousand in the prior partial period, with net income rising 624% to $3,951 thousand; however, total expenses surged 1,782% to $20,751 thousand, distributions sourced 8.2% from non-operating cash flows, and unrealized losses on loans payable stood at $(136) thousand.

• ·Cash flows from operating activities: $3,804 thousand for year ended Dec 31, 2025.
• ·Goldman Repurchase Agreement: Debt outstanding $161,677 thousand, available capacity $88,323 thousand, weighted average interest rate 5.92%.
• ·Citi Repurchase Agreement: Debt outstanding $115,575 thousand, available capacity $134,425 thousand, weighted average interest rate 5.48%.
• ·Total cash flows from operating activities since inception: $5,628 thousand.
• ·Unrealized gain on loans receivable: $340 thousand; unrealized loss on loans payable: $(136) thousand.

26-03-2026

Artelo Biosciences announced strategic expansion of ART27.13 development as a potential companion therapy to GLP-1 receptor agonists for preserving muscle mass during weight reduction, supported by CAReS trial observations of improved lean body mass, independent peer-reviewed research publication, a provisional patent filing on CB2 agonism for GLP-1 muscle loss mitigation, and initiation of a preclinical study. J.P. Morgan projects the global incretin market, including GLP-1 medicines, to reach $200 billion by 2030, with 25 million Americans potentially receiving GLP-1 treatments by then. In interim CAReS data, the highest-dose ART27.13 cohort showed average weight gain of approximately 6% versus approximately 5% weight loss in placebo-treated patients.

• ·Independent research publication: 'Kinetic multiplex assay to assess biased signaling of clinical GPCR agonists' describes ART27.13 as a superagonist among 17 clinically studied CB2 agonists.
• ·Third-party fully funded clinical study planned to start in Q2 2026 to evaluate ART27.13 in glaucoma patients.
• ·Provisional patent application filed covering cannabinoid receptor agonism to prevent or mitigate muscle loss with GLP-1 therapy.

26-03-2026

Corebridge Financial, Inc. has entered into a definitive all-stock merger agreement with Equitable Holdings, Inc., forming a leading retirement, life, wealth, and asset management company with more than 12 million customers and $1.5 trillion in assets under management and administration. The transaction is expected to deliver enhanced scale, diversification, expanded retirement capabilities, and a modernized customer experience, while maintaining operational continuity until closing. Closure is anticipated by year-end 2026, subject to regulatory approvals, shareholder votes, and customary conditions.

• ·Filing date: March 26, 2026
• ·Merger subject to customary closing conditions including regulatory approvals and shareholder approval
• ·Companies to operate separately until closing; no changes to client contacts

26-03-2026

TCW Steel City Senior Lending BDC reported net investment income loss of $(1,052) for the period from inception (February 5, 2025) to December 31, 2025, driven by total expenses of $9,474 exceeding total investment income of $8,422; however, a net realized gain of $14 and net unrealized appreciation of $1,780 on investments resulted in a net increase in net assets from operations of $742. The portfolio, with total investments at fair value of $724,129,154 and net assets of $118,723,974, showed mixed unrealized performance with gains in TechServ Operations ($1,103) and Centaur Holdings (Copperweld) ($500) offset by declines in Patriot MCN Buyer (McNichols) (-$101 and -$145) and others. Unfunded commitments totaled $80,872 with associated unrealized depreciation of $564.

• ·Credit facilities interest expense of $3,201 on average outstanding balance of $70,134 at weighted average rate of 6.45%.
• ·Interest rate sensitivity analysis shows net investment income (loss) ranging from $3,560 (up 300 bps) to $(2,683) (down 300 bps).
• ·Debt investments represent 286.1% of net assets, equity 1.2%, cash equivalents 2.2%, short-term investments 320.6%.
• ·Largest portfolio exposures: Charter Industries Holdings LLC and Patriot MCN Buyer Corp. (McNichols) at 32.2% and 33.0% of net assets respectively.

26-03-2026

Lucid Diagnostics Inc. (LUCD) filed an S-3/A amendment to its shelf registration statement (No. 333-291981) on March 25, 2026, enabling potential offerings of securities for working capital and general corporate purposes via an existing $25M ATM program with Maxim Group LLC. The filing emphasizes severe risks including ongoing operating losses since inception, substantial doubt about going concern status, limited revenues, heavy reliance on EsoGuard and EsoCheck products, and massive potential dilution from convertibles and equity plans. As of March 20, 2026, 176,945,972 common shares were outstanding, with over 80 million additional shares potentially issuable upon exercise/conversion, alongside no dividends expected.

• ·Authorized to issue 300,000,000 shares of common stock ($0.001 par) and 20,000,000 shares of preferred stock ($0.001 par).
• ·Stock options have weighted average exercise price of $1.57 per share.
• ·Annual automatic increase in shares available under 2018 Plan: 6% of outstanding common stock (through Jan 1, 2032).
• ·Annual automatic increase in shares under ESPP: lesser of 2% of outstanding common stock or 1,000,000 shares (through Jan 1, 2032).

26-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 26, 2026, under Item 8.01 to furnish a press release announcing that its RAD and Immix units are introducing 'SARA Alive Operating Inside Immix' following SIA NPS Category Award Recognition. The press release is attached as Exhibit 99.1 and is not deemed filed or material.

• ·Filing Date: March 26, 2026
• ·Event Date: March 26, 2026
• ·Principal Executive Offices: 10800 Galaxie Avenue, Ferndale, Michigan, United States 48220

26-03-2026

STRATA Skin Sciences, Inc. reported net revenues of $30,696 thousand for the year ended December 31, 2025, down 9% YoY from $33,562 thousand, driven by a 20% decline in international revenues while domestic revenues were essentially flat at a 1% decrease. Gross profit fell 7% to $17,881 thousand, but operating expenses decreased 21% to $22,581 thousand, primarily due to the absence of a $4,268 thousand goodwill impairment from 2024, resulting in a narrower operating loss of $4,700 thousand (improved 49% YoY). Loss before income taxes improved 39% to $6,249 thousand.

• ·Weighted average exercise price of outstanding options: $6.13
• ·No goodwill impairment in 2025 vs. $4,268 thousand in 2024
• ·Settlement gains of $1,135 thousand in 2025
• ·Engineering and product development expenses down 52% YoY to $421 thousand
• ·General and administrative expenses down 7% YoY to $10,184 thousand

26-03-2026

NewHold Investment Corp IV, a Cayman Islands blank check company focusing on industrial technology targets with $700 million+ enterprise value, filed Amendment No. 2 to its S-1 registration statement for a $175,000,000 IPO of 17,500,000 units at $10.00 each, consisting of one Class A ordinary share and one-third of a redeemable warrant exercisable at $11.50 post-business combination. Sponsor NewHold Industrial Technology IV LLC purchased 6,708,333 Class B founder shares for $25,000, causing substantial dilution to public shareholders, while private placements total $5,887,500 (up to $6,412,500 if over-allotment exercised) and non-managing sponsor investors expressed interest in $3,000,000 private units and up to 7,000,000 public units. Underwriters have a 45-day option for 2,625,000 additional units.

• ·Warrants exercisable 30 days after initial business combination, expire 5 years post-combination.
• ·Trust account withdrawals limited to $250,000 annually for working capital; no use for excise taxes.
• ·Non-managing sponsor investors to receive interests in 2,086,957 founder shares.
• ·Company address: 52 Vanderbilt Avenue, Suite 2005, New York, NY 10017.

26-03-2026

CIM Opportunity Zone Fund's 2025 annual results showed total revenues of $115,791, down 38% YoY from $187,931 due to a sharp 49% decline in solar revenue to $77,327, though rental income rose 8% to $38,464. The Fund achieved a net income attributable to the Fund of $78,701, swinging from a $6,584 loss in 2024, bolstered by a $117,364 realized gain on net investment in lease and higher other income, while total expenses remained nearly flat at $168,204. Total assets expanded 49% to $3,491,628, driven by growth in real estate investments to $2,642,532 net, but operating cash flow dropped to $19,430 from $87,597.

• ·Energy — Lemoore, CA asset cost: $1,150,076 with $284,802 encumbrances; portfolio includes seven assets (five operational, two construction-ready).
• ·Office — Los Angeles, CA (acquired 4/20/2023) occupancy: 0%.
• ·Office — Los Angeles, CA (acquired 1/4/2021) occupancy: 3%.
• ·Office — Los Angeles, CA (acquired 10/1/2019) occupancy: 10%.
• ·Notes payable at fair value increased to $512,758 from $295,464.

26-03-2026

Skyward Specialty Insurance Group, Inc. filed an amendment to its definitive proxy statement to correct iXBRL tagging errors in the Pay Versus Performance table for fiscal years 2025, 2024, and 2023. Net Income increased 43% YoY to $170.038M in 2025 from $118.839M in 2024, with the Internal Combined Ratio improving to 89.6% from 91.6%; however, Compensation Actually Paid declined sharply for PEO Andrew Robinson to $6,101,366 from $17,050,183 and for average non-PEO NEOs to $1,512,514 from $2,842,640, while SKWD TSR was relatively flat at $267.59 versus $264.61 YoY.

• ·Peer Group TSR declined slightly to $127.60 in 2025 from $128.30 in 2024.
• ·Four key performance measures linking CAP to NEOs: Internal Combined Ratio, Gross Written Premiums, Growth in Book Value Per Share, Absolute Stock Price.
• ·Non-PEO NEOs for 2025: Mark Haushill, John Burkhart, Patricia Ryan, Sandip Kapadia.

26-03-2026

News Corporation filed an 8-K disclosing updates on its ongoing $1 billion stock repurchase program, including information provided to the Australian Securities Exchange (ASX) attached as Exhibits 99.1 and 99.2. The program authorizes aggregate repurchases of up to $1 billion of Class A common stock (NWSA) and Class B common stock (NWS). No specific repurchase volumes or transactions are detailed in the body of the filing.

• ·Filing date: March 26, 2026; Earliest event date: March 25, 2026
• ·Securities: Class A Common Stock (NWSA) and Class B Common Stock (NWS) on Nasdaq Global Select Market

26-03-2026

Wave Life Sciences Ltd. issued a press release announcing positive interim data from the Phase 1 portion of its first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA (SpiNA design), in otherwise healthy individuals living with overweight or obesity. Management will host an investor conference call at 8:30 a.m. ET on March 26, 2026, to discuss the data, with an investor slide presentation available on the company's website.

• ·Investor conference call scheduled for 8:30 a.m. ET on March 26, 2026
• ·Investor slide presentation available at https://ir.wavelifesciences.com/

26-03-2026

GCI Liberty, Inc. shareholders are asked to elect Richard R. Green and Jedd Gould as Class I directors to serve until the 2029 annual meeting, with the Board unanimously recommending a vote FOR both nominees. The six-member Board, all appointed in 2025, is divided into three classes, with Class II (Larry E. Romrell, Brian M. Deevy) terms expiring in 2027 and Class III (Ronald A. Duncan, John C. Malone) in 2028. Four directors are independent, and the Board emphasizes diverse expertise in telecommunications, media, technology, and finance.

• ·Richard R. Green (age 88) joined July 2025; serves on Nominating & Corporate Governance (Chair), Audit, Compensation; prior CEO of CableLabs®.
• ·Jedd Gould (age 58) joined November 2025; serves on Audit; CEO of Mediabids.
• ·Brian M. Deevy (age 70) joined July 2025; prior Head of RBC CME Group.
• ·Larry E. Romrell (age 86) joined July 2025; extensive TCI executive experience.
• ·Ronald A. Duncan (age 73) joined July 2025; CEO of GCI since 2018.
• ·John C. Malone (age 85) joined July 2025; Chairman; extensive Liberty Media history.
• ·A plurality vote required for election; proxies may vote for substitutes if needed.
• ·2025 Form 10-K available free from Investor Relations.

26-03-2026

Prudential Financial's 2026 Proxy Statement outlines key leadership changes, including Charles F. Lowrey stepping down from the Board to become Senior Advisor until June 30, 2026, Caroline Feeney's departure after 33 years, and new appointments such as Phil Waldeck as EVP and Head of U.S. Businesses and Brad Hearn as President and CEO of Prudential Holdings of Japan. The company sold its PGIM Taiwan business and entered an agreement to sell its Kenya insurance operations to focus on higher-growth opportunities, while refreshing the Board with new independent directors Thomas D. Stoddard, Joseph J. Wolk, and Maryann Mannen effective May 12, 2026. The Annual Meeting agenda includes election of 11 directors, ratification of PricewaterhouseCoopers LLP as auditors, advisory vote on executive compensation, and a shareholder proposal for an independent Board Chairman.

• ·Annual Meeting of Shareholders scheduled for May 12, 2026, at 2:00 p.m. at 751 Broad Street, Newark, NJ 07102; record date March 13, 2026.
• ·Financial strength ratings as of February 3, 2026: A.M. Best (A+), Fitch (AA-), S&P (AA-), Moody’s (Aa3).
• ·More than half of employees work in Japanese operations.
• ·Board meeting held in Tokyo in November 2025 to discuss Asian business priorities.